No Detail Found!

Convalescent plasma for cvid-19 infection: evidence and clinical application

Author(s)
Ghassan Umair Shamshad Armed Forces Bone Marrow and Transplant Centre/National University of Medical Sciences (NUMS) Rawalpindi,Pakistan
Raheel Iftikhar Armed Forces Bone Marrow and Transplant Centre/National University of Medical Sciences (NUMS) Rawalpindi,Pakistan
Qamar Un Nisa Chaudhry Armed Forces Bone Marrow and Transplant Centre/National University of Medical Sciences (NUMS) Rawalpindi,Pakistan
Jehanzeb Ur Rehman Armed Forces Bone Marrow and Transplant Centre/National University of Medical Sciences (NUMS) Rawalpindi,Pakistan
Parvez Ahmed Armed Forces Bone Marrow and Transplant Centre/National University of Medical Sciences (NUMS) Rawalpindi,Pakistan
Abstract
Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus 2 (SARSCoV2) and has currently affected 11 million people worldwide with 0.53 million deaths. While there is ongoing trials and research for newer therapeutic options including antivirals (remdesivir), anti-interleukin 6 (tocilizumab), vaccines and antimalarials; there is renewed interest in the use of old therapeutic tools as well. Convalescent plasma has been used historically for measles, poliomyelitis, Spanish flu pandemic, severe acute respiratory syndrome (SARS1) and Ebola epidemics with conflicting results. With widespread use of convalescent plasma throughout the world as investigational drug for COVID-19, it is important to review past experience with its use in various outbreaks, potential role in COVID-19, and clinical application during current pandemic and challenges faced by resource constrained countries.
Publication Details
Page(s) 418-420
DOI DOI not available
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 70, Issue: 1, Year: 2020

Request the full text from PASTIC

Keywords
Mortality., Corona virus, Convalescent plasma
0

Citations

0

Downloads

79

Views